baber/WOPTO huggingface dataset:
Patent NZ-511937-A (NZ)
Title: Methods and compositions for targeting an activated vitronectin receptor with a ligand comprising adenovirus-2 penton base or fragment thereof
Inventor: SHATTIL SANFORD JACK
IPC: A61K48/00
Filed: 1999-12-03
Abstract: Disclosed are ligands that can selectively bind to activated alpha v beta 3 integrin. A monovalent ligand- mimetic (WOW-1 Fab) which includes a single alpha v integrin-binding domain from multivalent adenovirus penton base is provided. Further disclosed are particular compositions of activated alpha v beta 3-specific ligands, such as an antibody which immunoreacts preferentially with activated alpha v beta 3 integrin. Also described are methods using an activated alpha v beta 3-specific ligand for diagnostic detection of activated alpha v beta 3 integrin in tissues and for the targeted delivery of therapeutic agents to tissues containing activated alpha v beta 3 integrin.
Patent NZ-512051-A (NZ)
Title: Method of producing cyclene
Inventor: HOYER KARSTEN
IPC: C07D257/02
Filed: 1999-11-17
Abstract: A process for preparing cyclene (formula (I) comprising in a single-pot process: a) reacting triethylene tetramine with 40% glyoxal at 20 to 80oC in a polar protic solvent for 4 to 40 hours; b) after the solvent has been removed, the intermediate tricyclic compound formed in step a) is alkylated to the two secondary amine-nitrogens with a 1,2-difunctionalized alkylating agent X(CH2)2X in a polar aprotic solvent, optionally in the presence of an auxiliary base, at 20 to 120oC for 2 to 24 hours and X is a nucleofuge group; c) after the solvent has been removed, the condensation product formed in step b) is treated with hydrazine hydrate in a polar protic solvent at a pH of 3 to 6 for 12 to 48 hours at reflux temperature and d) then the cyclene is released from the cyclene salt by adding a base, and after the reaction solution is evaporated to the dry state, it is isolated.
Patent NZ-516773-A (NZ)
Title: Methods of inducing cell death using the E2 protein from papillomavirus
Inventor: GASTON KEVIN LEON
IPC: A61K48/00
Filed: 2000-07-13
Abstract: Disclosed are methods of inducing cell death and methods of killing cells using E2 and/or E7 proteins from papillomaviruses in non-human animals. Particularly disclosed is a method of inducing apoptosis of papillomavirus negative p53 wild-type, p53 mutant- or p53 related gene positive cells comprising contacting those cells with a papillomavirus E2 protein or a functional portion or derivative thereof or supplying to the cells a DNA sequence encoding a papillomavirus E2 protein or a functional portion or derivative thereof whereby apoptosis is induced in the cells. Such cells may be cancer or carcinoma cells, and may be infected with viruses, particularly oncogenic viruses or retroviruses such as HIV, HPV, Hepatitis B, Herpesvirus B, Epstein-Barr virus or Human T cell lymphotropic virus type 1 or 2.
Patent NZ-519593-A (NZ)
Title: Method for production of N-phosphonomethylglycine
Inventor: WULFF CHRISTIAN
IPC: C07F9/38
Filed: 2000-12-22
Abstract: A process for the preparation of N-phosphonomethylglycine, wherein a hexahydrotriazine derivative of the formula (II), wherein X is CN, COOZ, CONR1R2 or CH2OY, is reacted with a triacyl phosphite of the formula P(OCOR3)3 in which the radicals R3 are C1-C18 alkyl, or optionally substituted aryl and the product is hydrolysed and, if X is CH2OY, oxidized.
Patent NZ-523428-A (NZ)
Title: Neurotoxic oligomers
Inventor: BUSH ASHLEY
IPC: A61P21/00
Filed: 2001-06-28
Abstract: Disclosed are compositions for the treatment or alleviation of Alzheimer's disease and of other conditions related to abnormal protein aggregation. In particular, the treatment of and compositions for, the immunotherapy of Alzheimer's disease, Parkinson's disease, and cataract. In one aspect a method of prophylaxis, treatment or alleviation of a condition characterised by pathological aggregation and accumulation of a specific protein associated with oxidative damage and formation of tyrosine cross-links, comprising the step of immunizing a subject in need of such treatment with an immunizing-effective dose of one or more tyrosine cross-linked compounds, and optionally also comprising copper ions complexed to the compound is disclosed. Alternatively passive immunization against a tyrosine cross-linked compound may be used. Prophylactic or therapeutic compositions and diagnostic methods are also disclosed.
Patent NZ-523530-A (NZ)
Title: Mobile apparatus for complying with safety regulations
Inventor: DEAVILA PERICLES P
IPC: B62B3/10
Filed: 2001-06-07
Abstract: A mobile safety compliance apparatus comprising a shell with a plurality of open compartments closed by doors, a self-contained water supply system and a waste water collection system. The water supply system provides drinking water, tepid hand washing water, and water for a stowable eyewash hingedly attached to the shell. The waste water collection system collects water from the eyewash and a sink mounted in a recessed area of the shell. Doors are removable and have features to facilitate alternative uses such as a stretcher or a freestanding table. A stowable seat and table are hingedly attached to the shell. The apparatus includes an electrical system with battery backup for powering lights, water heating and refrigeration devices, and electronic communication equipment that may be mounted on the shell. The apparatus includes wheels to facilitate its movement and anchor points to secure it to the ground.
Patent NZ-524651-A (NZ)
Title: Chemokine receptor binding heterocyclic compounds for the treatment of HIV or FIV
Inventor: BRIDGER GARY
IPC: C07D521/00
Filed: 2001-09-17
Abstract: Heterocyclic compounds of formula (I) that modulate chemokine receptor activities are disclosed, wherein the substituents for the variables shown in formula (I) are as defined in the specification. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.
Patent NZ-525609-A (NZ)
Title: 3-aryolindole derivatives and their use as CB2 receptor agonists
Inventor: BARTH FRANCIS
IPC: A61P31/04
Filed: 2001-11-21
Abstract: Compounds of formula (I) are disclosed, and their preparation and pharmaceutical compositions containing them. The compounds are CB2 cannabinoid receptor agonists, in which: Ar represents: a) a phenyl mono-, di- or trisubstituted by one or more groups chosen from: a halogen atom, a (C1-C4)alkyl, a trifluoromethyl, an amino, a nitro, a hydroxyl, a (C1-C4)alkoxy, a (C1-C4)alkylsulphanyl or a (C1-C4)alkylsulphonyl; b) a naphthyl which is unsubstituted or substituted once or twice by a halogen atom, a (C1-C4)alkyl or a trifluoromethyl; A represents a C2-C6 alkylene radical; Y represents a group chosen from SR4, SOR4, SO2R4, SO2NR5R6, N(R7)SO2R4, OR4 or NR7SO2NR5R6; R1, R3 and R'3 represent, each independently of one another, hydrogen, a hydroxyl, a halogen atom, a (C1-C4)alkyl, a trifluoromethyl or a (C1-C4)alkoxy; R2 represents hydrogen or a (C1-C4)alkyl; R4 represents a (C1-C4)alkyl or a trifluoromethyl; R5 and R6 each independently represent hydrogen or a (C1-C4)alkyl; R7 represents hydrogen or a (C1-C4)alkyl and its optional salts and/or its solvates. The compound is useful in treating or preventing the following diseases or conditions: disorders of the immune system, diseases of the connective tissue, allergic diseases, viral or bacterial diseases, inflammatory diseases, pain, eye conditions, pulmonary conditions, diseases of the central nervous system and neurogenerative diseases, cardiovascular diseases, renal ischaemia, cancers, gastrointestinal diseases or obesity.
Patent NZ-527250-A (NZ)
Title: Occipital plate and system for spinal stabilization
Inventor: BERGER ROGER
IPC: A61B17/70
Filed: 2002-02-19
Abstract: An occipitocervical fixation system includes a plate (10) for securing to the occiput and at least one pre-bent rod (140). The plate includes holes (18) for receiving bone fasteners, and at least one clamping assembly (24, 26) for retaining a portion of a rod. The clamping assembly (24, 26) is selectively pivotable and lockable in place to fix the position of the rod.
Patent NZ-528945-A (NZ)
Title: Combination of brimonidine and timolol for topical ophthalmic use for the treatment of glaucoma and intraocular pressure
Inventor: CHANG CHIN-MING
IPC: A61K31/535
Filed: 2003-04-09
Abstract: An ophthalmic pharmaceutical composition useful in the treatment of glaucoma or ocular hypertension comprises an effective amount of brimonidine and timolol in a pharmaceutically acceptable carrier.
Patent NZ-529562-A (NZ)
Title: Use of type I interferon for the preparation of a non-toxic adjuvant composition for enhancing Th-1 type humoral immuno-response to a vaccine in an in vivo immunization treatment
Inventor: BELARDELLI FILIPPO
IPC: A61K47/48
Filed: 2002-04-16
Abstract: Described is the use of type I IFN for the preparation of a non toxic adjuvant composition for enhancing TH-1 type humoral immune response to a vaccine in an in vivo protective immunization treatment wherein IFN is used in a dosage greater or equal to 100,000 IU/ml, per dose of vaccine. Further described is a kit of parts including a non-toxic adjuvant composition comprising type I IFN and a vaccine including at least an antigen for separate, simultaneous or sequential use in the prevention or treatment of a disease associated with the presence of that antigen.
Patent NZ-544055-A (NZ)
Title: A bar connector assembly to couple adjacent reinforcing bars
Inventor: UNDERWOOD DANIEL CHARLES
IPC: E04C5/16
Filed: 2004-06-21
Abstract: A bar connector assembly configured to connect reinforcing bars is disclosed. The bar connector comprises a body having a bar seat section and a bar retainer moveable relative to the seat section to enable entry of a bar into the assembly. The seat section is adapted to receive and position a loop section of a second bar relative to a first bar already connected to the assembly. The retainer is moveable between a first position allowing the second bar to be placed on the seat section and a second position to block removal of the second bar from the assembly both in tension and compression.
Patent NZ-545618-A (NZ)
Title: Multilayer container trimming
Inventor: NAHILL THOMAS E
IPC: B65D1/16
Filed: 2005-03-31
Abstract: A method of making a plastic container (12) in accordance with one aspect of the present invention includes molding an intermediate container product (24) having a body (12) and a moil (26) integral with the body (12). The body is of layered construction that includes at least one layer of barrier resin that extends part-way into but not throughout the moil (26). The upper portion of the moil (26), in which the barrier material is absent, is removed and can be used for recycling as process regrind. The lower portion of the moil (26) is removed to form the container (12). In the preferred embodiment of the invention, the upper portion of the moil (26) is removed in a laser trimming operation.; The lower portion of the moil (26) is removed in the preferred embodiment of the invention by inserting a plug (not shown) into the open end or mouth of the container, and employing a cutting tool (not shown) that is positioned by the plug (not shown) for accurately trimming of the container product with respect to the mouth of the container (12). The cutting tool preferably is either a pair of shear rollers (not shown) or a laser cutting tool.
Patent NZ-546231-A (NZ)
Title: Drug containing (2R)-2-propyloctanoic acid as the active ingredient
Inventor: SUDOH MASAO
IPC: A61K9/06
Filed: 2004-10-01
Abstract: Disclosed is a drug containing from about one to five equivalents of a basic metal ion supplied from a metal salt of a weak acid or a metal hydroxide per equivalent of (2R)-2-propyloctaonic acid or its salt, which is useful in treating neurodegenerative diseases, optionally together with other additives. The above-described drug is a high-concentration drug which has a pH value suitable for intravenous administration, is highly tolerant to pH changes and remains transparent after diluted to prepare an infusion, thereby enabling the preparation of an injection and so on with the use of an arbitrary solvent and/or a diluting fluid.
Patent NZ-547563-A (NZ)
Title: Method of detecting a shellfish neurotoxin by detecting brevetoxin (BTX-B5) in a sample of the shellfish
Inventor: ISHIDA HITOSHI
IPC: C07D493/22
Filed: 2004-11-26
Abstract: Disclosed is a method for detecting a shellfish neurotoxin in shellfish comprising the step of detecting a compound of formula (I) in a sample of the shellfish .
Patent NZ-556764-A (NZ)
Title: A method and kit for determination of thymidine kinase activity and use thereof
Inventor: GRONOWITZ SIMON
IPC: C12Q1/48
Filed: 2006-02-24
Abstract: Provided is a method for determination of thymidine kinase (TK) activity in a biological sample comprising the steps of contacting, in a container containing a single stranded polynucleotide as a primer or template attached to a solid surface, a Basic Reaction Mixture, in a buffer, comprising the following components: a non-attached single stranded polynucleotide as a template and/or primer, a modified deoxy nucleoside as a kinase enzyme substrate, a phosphate donor, a nucleotide polymerizing enzyme, and a kinase enzyme source devoid of TK activity, with the biological sample, incubating the mixture, optionally washing the incubated mixture to remove non-attached reaction components, determining the amount of modified deoxy nucleoside that has been incorporated into the solid surface-attached primer or template and 15 determining the TK activity present in the biological sample from the amount of incorporated modified deoxy nucleoside. Further provided are corresponding assay kits and methods of diagnosis.
Patent NZ-562266-A (NZ)
Title: Sealing bar
Inventor: SPARAKOWSKI HELMUT
Filed: 2007-10-05
Abstract: A packaging machine for packaging contents in packs, which are produced from at least two sheets, includes a gas evacuation and gas flashing system with a suction system for extracting gas, in particular atmospheric air, from the packs, and a gas supply for supplying one or more gases such as nitrogen into the packs, and a pack sealing system for sealing the packs once the gas has been supplied. So that a predetermined gas flashing can be performed and the gas flashing is not performed whilst the packs are being evacuated, the pack sealing system closes the interior of the packs in relation to the suction by pressing the two sheets together prior to the gas being supplied.
Patent NZ-565172-A (NZ)
Title: Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
Inventor: VESCOVI ANGELO LUIGI
IPC: A61P35/00
Filed: 2006-07-19
Abstract: Provided is the use of a pharmaceutical composition in the manufacture of a medicament for treating a solid tumor in a subject characterized by excessive or misregulated cellular proliferation of at least one targeted cell type selected from the group consisting of a targeted tumor stem cell and a targeted tumor progenitor cell, the pharmaceutical composition comprising a therapeutic amount of at least one agent selected from the group consisting of a Bone Morphogenetic Protein (BMP) preparation, and a molecule capable of increasing BMP receptor (BMPR)-mediated signalling in the targeted tumor stem cell or targeted tumor progenitor cell (Bone Morphogenetic Protein Receptor (BMPR) signalling activator) in the targeted tumor stem cell or targeted tumor progenitor cell, wherein the therapeutic amount of the agent is effective to suppress the excessive or misregulated cellular proliferation of the tumor stem cell or the tumor progenitor cell by irreversibly reducing at least one of size, clonogenic index, or growth rate of the population of targeted tumor stem cells or targeted tumor progenitor cells.
Patent NZ-569412-A (NZ)
Title: Cleansing composition comprising ammonium
Inventor: LAUGEMAN FRITS JAN RUDOLF
IPC: C11D3/48
Filed: 2006-12-29
Abstract: Disclosed is a cleansing composition comprising an antimicrobial agent, a first sulphur binding agent, and optionally a second or further sulphur binding and/or oxidising agent, wherein the first sulphur binding agent is ammonium in an amount between 0.1 and 0.5 wt percent of the composition, wherein the anti-microbial agent is an organic acid selected from the group consisting of a hydroxy acid, citric acid, acetyl salicyclic acid, butyric acid, lactic acid, tartaric acid, acetic acid, malic acid, or mixtures of any of these acids; wherein the second sulphur binding and/or oxidizing agent is NaHCO3; wherein the fluoride source is NH2F and/or sodium fluoride (NaF);and wherein the pH of the composition is between 2 and 4. Also disclosed is a method of preparing the composition; the use of the composition for manufacturing a medicament for the treatment or prophylaxis or disorders of the naso and or oro pharynx such as halitosis, periodontitis, gingivitis and/or the treatment of human skin or vaginosis; and the use of the composition of cleaning prosthesis, surgical instruments, dental instruments and stainless steel dental and surgical instruments.
Patent NZ-569658-A (NZ)
Title: A novel dry stick device construction and method for determining an analyte in a sample using said dry stick device
Inventor: CLAUSEN KIM
IPC: B31B50/62
Filed: 2007-01-19
Abstract: Disclosed is a dry stick device for the determination of an analyte in a sample, said device comprises: (i) optionally a solid support, (ii) at least one reagent pad comprising a reagent or a combination of reagents capable of reacting with the analyte, a derivative of said analyte or an indicator compound for said analyte to provide a detectable signal when in a moistened state, the at least one reagent pad providing a first environment for said reagent(s), said first environment permitting an improved storage stability of the reagent(s) and dry stick device when in a non-moistened state, (iii) a regulating pad being in contact with the at least one reagent pad, the regulating pad creating a second environment for said reagent(s) when in a moistened state, said second environment permitting an increased rate of reaction between the analyte and the reagent(s), and wherein the sample is applied to one surface of the dry stick device and the detectable signal is detected on the same surface and wherein the determination of the analyte is based on an enzyme-based determination and wherein the condition in the first environment is provided by adjusting the pH-value to a value that deviates from the optimal pH-value of the enzyme(s) and wherein the condition in the second environment is provided by regulating the pH-value to a value that approaches the optimal pH-value of the enzyme(s) and wherein the different environments have different pH-values. Also disclosed is the method of making the disclosed dry stick device and the use of the dry stick device in determining an analyte in a sample.
Patent NZ-572767-A (NZ)
Title: Automated sensing, seasoning and transfer of food items to storage bin
Inventor: DORSTEN RON
IPC: A23L5/10
Filed: 2007-04-16
Abstract: A semi-automated food processing station, system and method is provided that allows food to be dispensed, stored and packaged in a suitable container, which may be an individual portion-sized container for serving to a customer. In one embodiment, the system includes an automated salting device, and may include a pivotable food receiving tray that automatically transfers the food items to one or more storage, bins, where an infrared heater maintains the temperature of the food items by directing infrared radiation thereon. In a preferred embodiment, the infrared radiation passes through a filter that filters out the wavelengths of infrared radiation that may be irritating to an operator.
Patent NZ-574012-A (NZ)
Title: Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
Inventor: KOHNO YASUSHI
IPC: C07C323/37
Filed: 2007-08-07
Abstract: Disclosed are (R)-2-amino-2-methyl-alkan-1-ols as represented by the general formula (1a) wherein R3 represents a straight chain alkyl group having 1 to 3 carbon atoms, X represents an oxygen atom or a sulfur atom , and n denotes 2 or 3; or a pharmaceutically acceptable salt or hydrate thereof. Of particular importance are the compounds (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylpentan-1-ol, (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylpentan-1-ol, (R)-2-amino-4-[2-chloro-4-(3-trifluoromethylphenoxy)phenyl]-2-methylbutan-1-ol, (R)-2-amino-4-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-methylbutan-1-ol and (R)-2-amino-5-[2-chloro-4-(3-trifluoromethylphenylthio)phenyl]-2-propylpentan-1-ol and pharmaceutically acceptable salts or hydrates thereof. Further disclosed is a pharmaceutical which comprises an amino alcohol derivative, or a pharmaceutically acceptable salt or hydrate thereof as defined above as an active ingredient for the prevention or treatment of rejection reactions in organ transplants or bone marrow transplants, or for use as an immunosuppressive agent.
Patent NZ-574425-A (NZ)
Title: Modulators of chemokine receptor activity, crystalline forms and process
Inventor: CARTER PERCY H
IPC: A61K31/4025
Filed: 2007-07-26
Abstract: Disclosed is N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-2-oxo-3-(6- (trifluoromethyl)quinazolin-4-ylamino)pyrrolidin-1-yl)cyclohexyl)acetamide, or a pharmaceutically acceptable salt thereof for treating a disease selected from diabetes, obesity, metabolic syndrome, stroke, neuropathic pain, ischemic cardiomyopathy, psoriasis, hypertension, scheroderma, osteoartm'itis, aneurism, fever, cardiovascular disease, Crohn's disease, congestive heart failure, autoimmune diseases, HIV-infection, HIV-associated dementia, psoriasis, idiopathic pulmonary fibrosis, transplant arteriosclerosis, physically- or chemically-induced brain trauma, inflammatory bowel disease, alveolitis, colitis, systemic lupus erythematosus, nephrotoxic serum nepm'itis, glomerulonephritis, asthma, multiple sclerosis, atherosclerosis, vasculitis, vulnerable plaques, rheumatoid arthritis, restenosis, venous neointimal hyperplasia, dialysis-graft neointimal hyperplasia, arterio-venous shunt intimal hyperplasia, organ transplantation, chronic allograft nephropathy, and cancer.
Patent NZ-574563-A (NZ)
Title: IDENTIFICATION OF A MICRO-RNA (miR-208) THAT ACTIVATES EXPRESSION OF BETA-MYOSIN HEAVY CHAIN FOR USE IN CARDIAC HYPERTROPHY CONDITIONS
Inventor: OLSON ERIC
IPC: A61K48/00
Filed: 2007-07-31
Abstract: Discloses the use of an engineered single-stranded oligonucleotide in the manufacture of a medicament for preventing or treating pathologic cardiac hypertrophy, heart failure, or myocardial infarction. The disclosed oligonucleotide is a modified small interfering RNA molecule that is complementary to a portion of gene sequence miR-208.